2 chapters across the catalog
Sluggish Cognitive Tempo, Daydreaming Disorder and Adderall
The Journal of Abnormal Child Psychology has introduced "Sluggish Cognitive Tempo" (SCT) as a new psychiatric diagnosis, which the hosts characterize as the medicalization of daydreaming. They argue this is an expansion of the ADHD market designed to sell more stimulants like Adderall to children.
Medical researchers have identified a new condition called Sluggish Cognitive Tempo (SCT), characterized by lethargy, daydreaming, and slow mental processing. Critics point out that prominent experts promoting the disorder, such as Dr. Russell Barkley, have significant financial ties to pharmaceutical companies like Eli Lilly, the manufacturer of Stratera. The hosts argue this is an attempt to expand the market for ADHD-style medications to include millions of additional children and adults.
